5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

5′-Nucleotidase (5NT) is an intrinsic membrane glycoprotein that is present as an enzyme in a wide variety of mammalian cells. It catalyzes the phosphorylytic cleavage of 5’nucleotides. The 5′ Nucleotidase drugs in development market research report provides an in-depth analysis of 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted pipeline therapeutics. The report provides comprehensive information on the 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

What are the therapy areas of the 5′ Nucleotidase pipeline drugs market?

The therapy areas of the 5′ Nucleotidase pipeline drugs market are oncology, infectious disease, and respiratory.

5′ Nucleotidase pipeline drugs market, by therapy areas

5′ Nucleotidase pipeline drugs market, by therapy areas

For more therapy area insights, download a free report sample

What are the indications of the 5′ Nucleotidase pipeline drugs market?

Some of the indications of the 5′ Nucleotidase pipeline drugs market are solid tumor, non-small cell lung cancer, ovarian cancer, unspecified cancer, pancreatic cancer, triple-negative breast cancer (TNBC), colorectal cancer, gastric cancer, head and neck cancer squamous cell carcinoma, and hepatocellular carcinoma.

5′ Nucleotidase pipeline drugs market, by indications

5′ Nucleotidase pipeline drugs market, by indications

For more indications insights, download a free report sample

What are the mechanisms of action of the 5′ Nucleotidase pipeline drugs market?

The mechanism of action of the 5′ Nucleotidase pipeline drugs market is 5′ Nucleotidase Inhibitor.

What are the routes of administration in the 5′ Nucleotidase pipeline drugs market?

The routes of administration in the 5′ Nucleotidase pipeline drugs market are intravenous, oral, and parenteral.

5′ Nucleotidase pipeline drugs market, by routes of administration

5′ Nucleotidase pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the 5′ Nucleotidase pipeline drugs market?

The molecule types in the 5′ Nucleotidase pipeline drugs market are monoclonal antibody, small molecule, antibody, antisense RNAi oligonucleotide, and antisense oligonucleotide.

5′ Nucleotidase pipeline drugs market, by molecule types

5′ Nucleotidase pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the 5′ Nucleotidase pipeline drugs market?

Some of the key companies in the 5′ Nucleotidase pipeline drugs market are Abbisko Therapeutics Co Ltd, Akeso Inc, Antengene Corp Ltd, Aprilbio Co Ltd, Arcus Biosciences Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, BioArdis LLC, BrightPath Biotherapeutics Co Ltd, and Bristol-Myers Squibb Co.

5′ Nucleotidase pipeline drugs market, by key companies

5′ Nucleotidase pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

Therapy Areas Oncology, Infectious Disease, and Respiratory
Indications Solid Tumor, Non-Small Cell Lung Cancer, Ovarian Cancer, Unspecified Cancer, Pancreatic Cancer, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Gastric Cancer, Head and Neck Cancer Squamous Cell Carcinoma, and Hepatocellular Carcinoma
Mechanisms of Action 5′ Nucleotidase Inhibitor
Routes of Administration Intravenous, Oral, and Parenteral
Molecule Types Monoclonal Antibody, Small Molecule, Antibody, Antisense RNAi Oligonucleotide, and Antisense Oligonucleotide
Key Companies Abbisko Therapeutics Co Ltd, Akeso Inc, Antengene Corp Ltd, Aprilbio Co Ltd, Arcus Biosciences Inc, AstraZeneca Plc, Aurigene Discovery Technologies Ltd, BioArdis LLC, BrightPath Biotherapeutics Co Ltd, and Bristol-Myers Squibb Co

This report provides:

  • A snapshot of the global therapeutic landscape of 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5).
  • Reviews of pipeline therapeutics for 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Key players involved in 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) therapeutics and enlists all their major and minor projects.
  • Assessment of 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • Summaries of all the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to 5′ Nucleotidase (Ecto 5’ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) targeted therapeutics.

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Abbisko Therapeutics Co Ltd
Akeso Inc
Antengene Corp Ltd
Aprilbio Co Ltd
Arcus Biosciences Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
BioArdis LLC
BrightPath Biotherapeutics Co Ltd
Bristol-Myers Squibb Co
Corvus Pharmaceuticals Inc
Eternity Bioscience Inc
Evotec SE
Harbour BioMed (Guangzhou) Co Ltd
I-Mab
Incyte Corp
Innate Pharma SA
Innovent Biologics Inc
InteRNA Technologies BV
iOnctura SA
Jacobio Pharmaceuticals Group Co Ltd
Les Laboratoires Servier SAS
Ligand Pharmaceuticals Inc
Merck & Co Inc
Novartis AG
ORIC Pharmaceuticals Inc
Phanes Therapeutics Inc
Secarna Pharmaceuticals GmbH & Co KG
Shanghai De Novo Pharmatech Co Ltd
Shanghai GeneChem Co Ltd
Shanghai Henlius Biotech Inc
Symphogen A/S
Trican Biotechnology Co Ltd
Verseon Corp
Zhejiang Borui Biopharmaceutical Co Ltd

Table of Contents

Table of Contents

Introduction

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC

3.1.3.5) – Overview

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC

3.1.3.5) – Therapeutics Development

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC

3.1.3.5) – Therapeutics Assessment

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC

3.1.3.5) – Companies Involved in Therapeutics Development

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC

3.1.3.5) – Drug Profiles

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC

3.1.3.5) – Dormant Products

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC

3.1.3.5) – Discontinued Products

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC

3.1.3.5) – Product Development Milestones

Appendix

Table

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Indications, 2021 (Contd..2)

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Products under Development by Companies, 2021 (Contd..5)

Products under Development by Companies, 2021 (Contd..6)

Products under Development by Companies, 2021 (Contd..7)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Abbisko Therapeutics Co Ltd, 2021

Pipeline by Akeso Inc, 2021

Pipeline by Antengene Corp Ltd, 2021

Pipeline by Aprilbio Co Ltd, 2021

Pipeline by Arcus Biosciences Inc, 2021

Pipeline by AstraZeneca Plc, 2021

Pipeline by Aurigene Discovery Technologies Ltd, 2021

Pipeline by BioArdis LLC, 2021

Pipeline by BrightPath Biotherapeutics Co Ltd, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by Corvus Pharmaceuticals Inc, 2021

Pipeline by Eternity Bioscience Inc, 2021

Pipeline by Evotec SE, 2021

Pipeline by Harbour BioMed (Guangzhou) Co Ltd, 2021

Pipeline by I-Mab, 2021

Pipeline by Incyte Corp, 2021

Pipeline by Innate Pharma SA, 2021

Pipeline by Innovent Biologics Inc, 2021

Pipeline by InteRNA Technologies BV, 2021

Pipeline by iOnctura SA, 2021

Pipeline by Jacobio Pharmaceuticals Group Co Ltd, 2021

Pipeline by Les Laboratoires Servier SAS, 2021

Pipeline by Ligand Pharmaceuticals Inc, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Novartis AG, 2021

Pipeline by ORIC Pharmaceuticals Inc, 2021

Pipeline by Phanes Therapeutics Inc, 2021

Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021

Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2021

Pipeline by Shanghai GeneChem Co Ltd, 2021

Pipeline by Shanghai Henlius Biotech Inc, 2021

Pipeline by Symphogen A/S, 2021

Pipeline by Trican Biotechnology Co Ltd, 2021

Pipeline by Verseon Corp, 2021

Pipeline by Zhejiang Borui Biopharmaceutical Co Ltd, 2021

Dormant Projects, 2021

Discontinued Products, 2021

Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently asked questions

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update in real time.

  • Access a live 5′ Nucleotidase (Ecto 5′ Nucleotidase or CD73 or NT5E or EC 3.1.3.5) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.